Skip to Main Content

WASHINGTON — The drug pricing advocates who once trounced President Obama for his proposal to shield expensive biologic drugs from competition are now girding for a fight with President Trump over his new trade pact. But their jabs feel softer this round.

The president can take some of the credit for slipping those punches.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED